Clopidogrel and proton-pump inhibitor interaction: viewpoint and practical clinical approach

Br J Cardiol 2011;18:84−7 Leave a comment
Click any image to enlarge
Authors:

The role of clopidogrel after percutaneous coronary intervention (PCI) or acute coronary syndrome (ACS) is well supported by strong clinical evidence, which has led to a dramatic increase in its use. 

The use of a combination of proton-pump inhibitors (PPIs) and clopidogrel has recently been questioned due to pharmacological interaction, with possible implications and effects on clinical outcome in patients using this combination. This has brought uncertainty and confusion into clinical practice. 

There is a definite interaction between the two drugs, at a pharmacodynamic level; however, the clinical relevance remains uncertain.

In this article I will review the subject and suggest a management strategy, which I hope will be of help to clinicians dealing with these patients on a daily basis.

Pay to access this premium content £5

The BJC is introducing a small charge for some of its premium content. On purchase you will receive an email to access the article and have a downloadable PDF to keep. The PDF can be downloaded from a button on the sidebar. Please note the purchase of this article is for your personal use only.
By supporting us in this way, you are helping us to deliver high-quality services to healthcare professionals. We will continue to keep the majority of our content free of charge.


You can access this article without logging in.
But don't miss out on the many Benefits of our Membership. Register Now.
Already a member? Login Now.
THERE ARE CURRENTLY NO COMMENTS FOR THIS ARTICLE - LEAVE A COMMENT